All In Biotech

Drug Trial Radar · NCT07021157

A Study to Evaluate the Safety, Tolerability and PK of SK-08

A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Single-dose Increasing of SK-08 Tablets in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Mar 9, 2025

Primary completion

Aug 7, 2025

Study completion Aug 7, 2025

Sponsor

Lead sponsor
Consun Pharmaceutical GroupIndustry
Sponsor type
Industry
First posted
Jun 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The trial is conducted in a single-center, randomized, double-blind, placebo-controlled, dose-increasing design. To evaluate the safety, tolerability, pharmacokinetics(PK) ,and pharmacodynamics (PD) characteristics of SK-08 in healthy participants.

Conditions

  • Chronic Kidney Disease(CKD)

Interventions

  • SK-08Drug

    Dose groups of 5 mg, 7.5mg,12.5 mg, 30 mg, 45 mg, and 60 mg were given SK-08 once.

  • PlaceboDrug

    Dose groups of 5 mg, 7.5mg,12.5 mg, 30 mg, 45 mg, and 60 mg were given placebo once.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety EvaluationTime frame: up to Day 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital,Zhejiang University

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.